Four Weeks of A Neuro-meditation Program Improves Sleep Quality And Reduces Hypertension In Nursing Staff: A parallel randomized controlled trial

Four Weeks of A Neuro-meditation Program Improves Sleep Quality And Reduces Hypertension In Nursing Staff: A parallel randomized controlled trial - Neuro-meditation improves sleep quality

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

DRKS

Registry ID

DRKS00025731

Enrollment

Registered

2021-08-10

Start date

2020-05-31

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I10.00 F51.8

Interventions

Group 1: Neuro-meditation 10 x 30-min sessions across 4 weeks in participants with hypertension Group 2: Neuro-meditation 10 x 30-min sessions across 4 weeks in participants without hypertension Group

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Nursing staff in hospitals and assisted living facilities

Exclusion criteria

Exclusion criteria: Participants who showed premature heart beats or serious abnormal heart rhythms; muscular and/or joint disorders; were on blood pressure medication or suffered from anxiety; current inflammatory disorder; sleep apnoea; restless legs syndrome; illness, or infection (e.g., autoimmune disease, type 1 diabetes mellitus, hepatitis C, cancer); or acute infection in the past 2 weeks.

Design outcomes

Secondary

Measure	Time frame
Blood pressure Diastolic and systolic blood pressure were measured seated by electrosphygmomanometry (Tango+; Suntech Medical, Flaxlanden, France) pre- and post-intervention.	—

Primary

Measure	Time frame
Sleep quality Sleep was monitored across four, three-day periods at Baseline (three nights prior to the Rebalance© program), and for three nights following the third (REB-3), sixth (REB-6) and ninth (REB-9) Rebalance© session. Participants wore an Actiwatch sleep monitor (Cambridge Neurotechnology Ltd., Cambridge, UK) on the nondominant wrist with the epoch length set to 1 min. The watch was worn at all times of the day (other than when the watch could get wet) for each monitoring period. Participants were monitored the 3 d prior to Baseline testing, REB 3, REB 6 and REB 9. Mean behavioral activity over each recording period was automatically calculated using the Sleepwatch sleep analysis software (version 5.28, Cambridge Neurotechnology Ltd.). The Spiegel Questionnaire for Sleep Quality and the Ford Insomnia Response to Stress Test were completed pre- and post-intervention.	—

Measure

Time frame

Sleep quality Sleep was monitored across four, three-day periods at Baseline (three nights prior to the Rebalance© program), and for three nights following the third (REB-3), sixth (REB-6) and ninth (REB-9) Rebalance© session. Participants wore an Actiwatch sleep monitor (Cambridge Neurotechnology Ltd., Cambridge, UK) on the nondominant wrist with the epoch length set to 1 min. The watch was worn at all times of the day (other than when the watch could get wet) for each monitoring period. Participants were monitored the 3 d prior to Baseline testing, REB 3, REB 6 and REB 9. Mean behavioral activity over each recording period was automatically calculated using the Sleepwatch sleep analysis software (version 5.28, Cambridge Neurotechnology Ltd.). The Spiegel Questionnaire for Sleep Quality and the Ford Insomnia Response to Stress Test were completed pre- and post-intervention.

—

Countries

France

Contacts

Public ContactChristophe Hausswirth

Cote d'Azur University

hausswirthc@gmail.com0686584693

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 12, 2026